Current understanding of AD pathophysiology and impact of amyloid‐beta targeted treatments on biomarkers and clinical endpoints
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| Online Access: | https://doi.org/10.1002/trc2.12361 |
| _version_ | 1797949000549138432 |
|---|---|
| author | Ronald C. Petersen Ana Graf Maria C. Carrillo Christopher J. Weber |
| author_facet | Ronald C. Petersen Ana Graf Maria C. Carrillo Christopher J. Weber |
| author_sort | Ronald C. Petersen |
| collection | DOAJ |
| first_indexed | 2024-04-10T21:52:25Z |
| format | Article |
| id | doaj.art-9c8a02b31379448c85dc22ad3109b93e |
| institution | Directory Open Access Journal |
| issn | 2352-8737 |
| language | English |
| last_indexed | 2024-04-10T21:52:25Z |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| spelling | doaj.art-9c8a02b31379448c85dc22ad3109b93e2023-01-18T11:41:04ZengWileyAlzheimer’s & Dementia: Translational Research & Clinical Interventions2352-87372022-01-0181n/an/a10.1002/trc2.12361Current understanding of AD pathophysiology and impact of amyloid‐beta targeted treatments on biomarkers and clinical endpointsRonald C. Petersen0Ana Graf1Maria C. Carrillo2Christopher J. Weber3Mayo Clinic Alzheimer's Disease Research Center Rochester Minnesota USANovartis Pharma AG Klybeckstrasse, 4057 Basel Basel SwitzerlandAlzheimer's Association Chicago Illinois USAAlzheimer's Association Chicago Illinois USAhttps://doi.org/10.1002/trc2.12361 |
| spellingShingle | Ronald C. Petersen Ana Graf Maria C. Carrillo Christopher J. Weber Current understanding of AD pathophysiology and impact of amyloid‐beta targeted treatments on biomarkers and clinical endpoints Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| title | Current understanding of AD pathophysiology and impact of amyloid‐beta targeted treatments on biomarkers and clinical endpoints |
| title_full | Current understanding of AD pathophysiology and impact of amyloid‐beta targeted treatments on biomarkers and clinical endpoints |
| title_fullStr | Current understanding of AD pathophysiology and impact of amyloid‐beta targeted treatments on biomarkers and clinical endpoints |
| title_full_unstemmed | Current understanding of AD pathophysiology and impact of amyloid‐beta targeted treatments on biomarkers and clinical endpoints |
| title_short | Current understanding of AD pathophysiology and impact of amyloid‐beta targeted treatments on biomarkers and clinical endpoints |
| title_sort | current understanding of ad pathophysiology and impact of amyloid beta targeted treatments on biomarkers and clinical endpoints |
| url | https://doi.org/10.1002/trc2.12361 |
| work_keys_str_mv | AT ronaldcpetersen currentunderstandingofadpathophysiologyandimpactofamyloidbetatargetedtreatmentsonbiomarkersandclinicalendpoints AT anagraf currentunderstandingofadpathophysiologyandimpactofamyloidbetatargetedtreatmentsonbiomarkersandclinicalendpoints AT mariaccarrillo currentunderstandingofadpathophysiologyandimpactofamyloidbetatargetedtreatmentsonbiomarkersandclinicalendpoints AT christopherjweber currentunderstandingofadpathophysiologyandimpactofamyloidbetatargetedtreatmentsonbiomarkersandclinicalendpoints |